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The emergence of multi-drug resistant (MDR) microbial pathogens threatens the very foundation upon which
standard antibacterial chemotherapy is based. We must consider non-antibiotic solutions to manage invasive
bacterial infections. Transition from antibiotics to non-traditional treatments poses real clinical challenges that will
not be easy to solve. Antibiotics will continue to reliably treat some infections (e.g., group A streptococci and
Treponema pallidum) but will likely need adjuvant therapies or will need to be replaced for many bacterial
infections in the future.
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Recent discoveries of plasmid-transferable genes that
mediate resistance to carbapenems [1] and colistin [2]
indicate that the last defensive wall against multi-drug
resistant (MDR) pathogens has already been breached.
We now face the uncomfortable reality that the post-
antibiotic era has arrived when dealing with pan-
resistant bacterial pathogens. We need to consider our
remaining options and develop new ones in a world
where antibiotics can no longer be counted upon to cure
infections. Non-antibiotic opportunities to treat serious
bacterial infections exist as possible options (Table 1).
Hemofiltration devices
Extracorporeal pathogen removal filters are in develop-
ment which can bind and remove an array of blood
stream pathogens. Multiple device filters are being stud-
ied; two of the more interesting ones include the use of
mannose binding lectins [3] or bound heparin [4]. Re-
duction in the bacterial load by hemofilters could theor-
etically allow the host innate and adaptive immune
systems to remove residual pathogens despite pan-
resistance to antimicrobial agents.
Quorum sensing inhibitors
Many bacteria employ some form of intercellular com-
munication to alert pathogens about their collective bac-
terial concentration. If high concentrations are detected,
pathogens can switch their transcription profiles to an
invasive phenotype [5, 6]. An impressive array of natural
and synthetic molecules can block quorum sensing and
improve outcomes in experimental models of systemic
infection. Whether quorum sensing inhibitors will ever
be of practical clinical benefit against MDR pathogens
remains the subject of considerable debate [5, 6].
Lytic bacteriophages
The use of bacteriophages (viruses that lyse specific bac-
teria) as a replacement for antimicrobial agents against
MDR pathogens remains an attractive option despite nu-
merous challenges [7, 8]. Phage therapy to treat bacterial
infection was introduced in the early 1920s and is still in
clinical use in some regions in Eastern Europe and in
Georgia [8]. Phage therapy is now regaining widespread
interest as antimicrobial resistance is reaching a global
crisis.
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Bacteriolysis by selected lytic phages is likened to the
activity of a rapidly bactericidal antibiotic against suscep-
tible bacteria. Phage invade bacteria via attachment to
surface receptors on bacteria where they replicate intra-
cellularly and kill the bacterial host by digesting the pep-
tidoglycan cell wall. Phage are ubiquitous in nature and
are harmlessly ingested in our diet by the millions each
day [8]. Phage therapy can be administered topically on
open wounds or surface infections [7] or given intraven-
ously for use in systemic infections.
Despite all the theoretical advantages of phage therapy
for MDR pathogens, numerous drawbacks and practical
challenges exist. The major problem is their exquisite
specificity. Phage infect only one strain of bacteria,
thereby precluding their use as empiric therapy for acute
infections. The causative bacterium responsible for the
infection must be identified; then a suitable phage ther-
apy can be fashioned from existing stocks of phage.
Stocking a hospital laboratory with a complete library of
phage for every conceivable bacterial pathogen will be a
major challenge indeed [8].
Advanced immunotherapies
Immunotherapy to treat infectious diseases is not a new
idea, but innovations in the generation of high affinity,
human polyclonal or monoclonal antibodies against an
array of molecular targets makes this an attractive ap-
proach. Active immunizations with adjuvanted, multi-
eptitope bacterial vaccines are in development, as are
monoclonal and polyclonal antibodies, as passive therap-
ies against bacterial pathogens [9–11]. Transchromoso-
mic cattle have been developed that can deliver high
volumes of high quality, human polyclonal antibodies
against bacterial and viral antigens [11]. Monoclonal
antibodies can be designed with advantageous features
and half-lives that can opsonize bacteria or inhibit viru-
lence factors without the need for antibiotics [9, 10].
Immune adjuvants are in clinical development to
booster cellular and humoral adaptive immunity of the
host [12]. A number of adjuvants are under investiga-
tion, including interleukin-7, granulocyte macrophage-
colony stimulating factor, programmed cell death
ligand-1 antibody, among other strategies. Such im-
mune adjuvants could benefit patients with sepsis-
induced immune suppression [12].
Alternative efforts to limit virulence
Liposome-based cyto-toxin inhibitors [13] have been
engineered to capture a variety of cell membrane lytic
toxins produced by bacteria. These liposomes serve as
cell membrane decoys to absorb cyto-toxins and thereby
protect human cells from injury. This non-antibiotic
defense mechanism is protective experimentally and
could complement anti-microbial agents in treating
exotoxin-producing bacterial infections.
Non-immune tolerance to pathogens
Non-immune tolerizing events allow the host to survive
and co-exist in the presence of a potential microbial
threat. This represents a novel way of approaching the
problem of MDR pathogens [14, 15]. Treatments would
be aimed at allowing the host to compensate for pathogen
presence until immune clearance removes the pathogen.
An example of non-immune tolerance is seen in the dif-
ferential susceptibility of mice (and likely humans) to
Ebola virus disease [15]. Mouse strains vary dramatically
in their susceptibility to the same strain and dose of Ebola
virus. The genetic explanation is found primarily in the
variation of expression of a single gene known as Tek, the
human homologue for tyrosine kinase receptor for
angiopoietin-1. High levels of angiopoietin1/Tie2 promote
Table 1 Summary of some non-antibiotic inhibitors of bacterial growth and/or pathogenesis
Treatment strategy Mechanism of action Possible benefits
Hemoperfusion devices [3, 4] Extracorporeal filters that clear blood pathogens
by their physiochemical properties
Quickly reduce blood concentrations of selected
bacteria by orders of magnitude
Quorum sensing inhibitors [5, 6] Disrupt intercellular signaling between bacteria
to block coordinated tissue invasion
Blocks sensing of necessary concentrations of
bacteria for optimal synthesis of virulence and
invasion genes
Lytic bacteriophage [7, 8] Bacteriolysis induced by selected lytic phage or
phage cocktails
Parasitic predators of bacteria that can be used
as highly specific, targeted, bactericidal agents
Polyclonal or monoclonal antibodies [9–11];
immune adjuvants [12]
Improved bacterial vaccines, transgenic cattle for
polyclonal immunotherapy; designer monoclonal
antibodies; immune-stimulant therapy for sepsis
induced immunosuppression
Active or passive immunotherapy to opsonize
bacteria or inhibit exotoxins and virulence factors;
adjuvants to stimulate cellular immune function
Liposome-based cyto-toxin inhibitors [13] Engineered liposomes to serve as cell membrane
decoys to absorb bacterial cyto-toxins
Capture pore-forming cyto-toxins and protect
host cell membranes from cellular injury
Non-immune toleralizing approaches [14, 15] Treatments allowing the host to survive and
compensate for pathogen presence or until
immune clearance removes the pathogen
Permits the host to tolerate the pathogen until
cleared by immune or non-immune mechanisms
(e.g., oral or intravenous fluids for cholera)
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endothelial barrier protection. Ebola viruses specifically
target the endothelium and kill endothelial cells. Mouse
strains with high levels of Tek are better able to defend
their endothelial surfaces until the adaptive immune cells
(cytotoxic CD8 cells) arrive at about 7 days into infection
to clear the virus. Perhaps non-immune therapeutics
against infectious diseases might provide some options
against MDR pathogens in clinical medicine.
Summary
The progressive spread of antibiotic resistance genes is
forcing us to reconsider our treatment options against
some bacterial pathogens. Treating bacterial infections
will likely become more challenging in the future. We
need to protect the antibiotics we already have, develop
new ones, and redouble our efforts to generate novel
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